PE20050086A1 - Combinacion farmaceutica que comprende eletriptan o una sal farmaceuticamente aceptable y bicarbonato de sodio - Google Patents

Combinacion farmaceutica que comprende eletriptan o una sal farmaceuticamente aceptable y bicarbonato de sodio

Info

Publication number
PE20050086A1
PE20050086A1 PE2004000356A PE2004000356A PE20050086A1 PE 20050086 A1 PE20050086 A1 PE 20050086A1 PE 2004000356 A PE2004000356 A PE 2004000356A PE 2004000356 A PE2004000356 A PE 2004000356A PE 20050086 A1 PE20050086 A1 PE 20050086A1
Authority
PE
Peru
Prior art keywords
pharmaceutically acceptable
sodium bicarbonate
combination including
acceptable salt
pharmaceutical combination
Prior art date
Application number
PE2004000356A
Other languages
English (en)
Inventor
Michael John Humphrey
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0308469A external-priority patent/GB0308469D0/en
Priority claimed from GB0312479A external-priority patent/GB0312479D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of PE20050086A1 publication Critical patent/PE20050086A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UNA COMBINACION QUE COMPRENDE: (a) ELETRIPTAN, 3-{[1-METIL-PIRROLIDIN-2-(R)-IL]METIL}-5-(2-FENILSULFONIL-ETIL)-1H-INDOL, O UNA DE SUS SALES FARMACEUTICAMENTE ACEPTABLES, Y (b) BICARBONATO DE SODIO PARA SU USO EN EL TRATAMIENTO O LA PREVENCION DE UNA ENFERMEDAD PARA LA QUE ES INDICADO UN AGENTE AGONISTA DE 5-HT1, PARTICULARMENTE PARA SU USO EN EL TRATAMIENTO DE UNA MIGRANA O EN LA PREVENCION DE UNA RECURRENCIA DE MIGRANA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA ADAPTADA PARA LA ADMINISTRACION POR VIA ORAL EN FORMA DE TABLETA O EN FORMA DE UNA COMPOSICION NO EFERVESCENTE
PE2004000356A 2003-04-11 2004-04-07 Combinacion farmaceutica que comprende eletriptan o una sal farmaceuticamente aceptable y bicarbonato de sodio PE20050086A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0308469A GB0308469D0 (en) 2003-04-11 2003-04-11 Pharmaceutical combination
GB0312479A GB0312479D0 (en) 2003-05-30 2003-05-30 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
PE20050086A1 true PE20050086A1 (es) 2005-03-01

Family

ID=33161221

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2004000356A PE20050086A1 (es) 2003-04-11 2004-04-07 Combinacion farmaceutica que comprende eletriptan o una sal farmaceuticamente aceptable y bicarbonato de sodio

Country Status (12)

Country Link
EP (1) EP1615635A1 (es)
JP (1) JP2006522790A (es)
AR (1) AR044009A1 (es)
BR (1) BRPI0409127A (es)
CA (1) CA2521902A1 (es)
MX (1) MXPA05010070A (es)
NL (1) NL1025908C2 (es)
PA (1) PA8599901A1 (es)
PE (1) PE20050086A1 (es)
TW (1) TW200423929A (es)
UY (1) UY28260A1 (es)
WO (1) WO2004089365A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
JP6878021B2 (ja) * 2016-02-02 2021-05-26 第一三共ヘルスケア株式会社 トリプタンとアスコルビン酸を含有する医薬組成物
AU2019297360B2 (en) 2018-07-03 2022-07-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1197038B (it) * 1986-08-01 1988-11-25 Zambon Spa Composizione farmaceutica ad attivita' analgesica
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
IT1272149B (it) * 1993-03-26 1997-06-11 Zambon Spa Composizione farmeceutiche ad attivita' analgesica
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US6488961B1 (en) 1996-09-20 2002-12-03 Ethypharm, Inc. Effervescent granules and methods for their preparation
GB9704524D0 (en) * 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB9816556D0 (en) 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
IL136025A0 (en) * 1999-05-14 2001-05-20 Pfizer Prod Inc Combination therapy for the treatment of migraine
GB0018968D0 (en) 2000-08-02 2000-09-20 Pfizer Ltd Particulate composition
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
GB0129117D0 (en) * 2001-12-05 2002-01-23 Glaxo Group Ltd Pharmaceutical composition
JP2006523620A (ja) * 2003-02-19 2006-10-19 バイオヴェイル ラボラトリーズ インコーポレイテッド 急速吸収選択的５−ｈｔ作用剤製剤

Also Published As

Publication number Publication date
EP1615635A1 (en) 2006-01-18
MXPA05010070A (es) 2005-11-23
WO2004089365A1 (en) 2004-10-21
PA8599901A1 (es) 2005-02-04
UY28260A1 (es) 2004-11-30
AR044009A1 (es) 2005-08-24
NL1025908A1 (nl) 2004-10-13
CA2521902A1 (en) 2004-10-21
TW200423929A (en) 2004-11-16
BRPI0409127A (pt) 2006-03-28
NL1025908C2 (nl) 2005-11-22
JP2006522790A (ja) 2006-10-05

Similar Documents

Publication Publication Date Title
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
MA29799B1 (fr) Administration d'inhibiteurs de dipeptidyl peptidase
CL2004000643A1 (es) Composicion farmaceutica que comprende un agonista de 5-ht 1b/1d y un inhibidor selectivo de ciclooxigenasa-2, util en el tratamiento de la migrana.
PE20120654A1 (es) Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona
CO5070571A1 (es) Preparado farmaceutico de moxifloxacina
DE60032749D1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
PT833618E (pt) Forma farmaceutica solida para utilizacao oral
PE20030347A1 (es) Composiciones farmaceuticas, kits y procedimientos que comprenden combinaciones de agonistas/antagonistas de estrogenos, estrogenos y progestinas
PE20010952A1 (es) Composicion para dosis oral de liberacion extendida
RU2016122609A (ru) Составы соединений азаиндола
ES2255287T3 (es) Composiciones para el tratamiento de la leucemia linfocitica cronica.
GT200500309A (es) Derivados de sulfonilbencilimidazol
PA8669801A1 (es) Asociacion entre la ferroquina y un derivado de artemisinina para el tratamiento del paludismo
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
AR031679A1 (es) Una composicion farmaceutica
GT200100149A (es) Composicion de eletriptan en forma de particulas.
PE20050086A1 (es) Combinacion farmaceutica que comprende eletriptan o una sal farmaceuticamente aceptable y bicarbonato de sodio
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
AR022621A1 (es) Composicion farmaceutica que contiene desoxipeganina para el tratamiento de la dependencia de la nicotina
CO5611148A2 (es) Composiciones farmaceuticas de un inhibidor de pde4 o pde3/4 y un antagonista receptor de histamina
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
AR033807A1 (es) Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y de sus sales aceptables para uso fisiologico, y las composiciones farmaceuticas que contiene estos compuestos
HUP0400495A2 (hu) Apomorfin szájnyálkahártyán keresztül történő adagolására szolgáló orális készítmény
PE20010123A1 (es) Agonistas del receptor 5ht1 y un inhibidor de la cox-2 o un aine para el tratamiento de la migrana
AR052138A1 (es) Composicion farmaceutica de liberacion lenta que comprende (+)-(2s,3s)-2-(3-clorofenil)-3,5,5-trimetil-2- morfolinol y su uso para la elaboracion de un medicamento

Legal Events

Date Code Title Description
FD Application declared void or lapsed